NXP200 Wins China Breakthrough Therapy Designation for BRAF V600-Mutant High-Grade Glioma
核心洞察
China's Center for Drug Evaluation (搜索) granted Breakthrough Therapy Designation to Nuvectis and Haisco's oral, brain-penetrant BRAF (搜索) inhibitor NXP200 (搜索) for BRAF V600-mutant recurrent or progressive high-grade glioma (搜索).
The designation follows a completed dose-escalation study in which single-agent NXP200 (搜索) produced responses in more than 40% of heavily pretreated adult low- and high-grade glioma (搜索) patients, including one complete response.
NXP200 (搜索) is designed as a paradox-breaker that shuts down the BRAF (搜索) pathway without the paradoxical reactivation that limits first-generation BRAF inhibitors and drives resistance to them.
China's Center for Drug Evaluation (搜索) has granted Breakthrough Therapy Designation to NXP200 (搜索), an oral, brain-penetrant BRAF (搜索) inhibitor, for the treatment of BRAF V600-mutant, recurrent or progressive high-grade glioma (搜索). The designation was granted to Haisco Pharmaceutical Group (搜索), Nuvectis Pharma's partner in China, and covers a disease described as an aggressive brain cancer with few effective options once it returns.
Nuvectis holds ex-China rights to NXP200 (搜索). The designation is reserved for drugs treating serious conditions where early data point to a meaningful advantage over existing therapy, and it brings closer regulator guidance and potentially a faster review once an application is filed.
Dose-Escalation Data Behind the Designation
The designation follows a completed dose-escalation study in which NXP200 (搜索), administered on its own, produced responses in more than 40% of adult low- and high-grade glioma (搜索) patients, including one complete response, in a heavily pretreated group.
NXP200 (搜索) is designed as a "paradox-breaker," shutting down the BRAF (搜索) pathway without the paradoxical reactivation that limits first-generation BRAF drugs and drives resistance to them. Chief executive Ron Bentsur said the designation "underscores the compelling clinical activity observed to date." Nuvectis still expects to file a U.S. IND for NXP200 in the fourth quarter.
Two Regulators, One Drug Class
The Chinese designation lands in a corner of oncology that regulators are prioritizing. In April, the FDA granted its own Breakthrough Therapy Designation to FORE Biotherapeutics (搜索)' plixorafenib, another brain-penetrant, paradox-breaking BRAF (搜索) inhibitor, for adults with BRAF V600E-mutated high-grade glioma (搜索). Two regulators on two continents have now granted breakthrough status to the same drug class, for closely overlapping patient populations, within six months of each other.
Differentiation From First-Generation BRAF Inhibitors
Nuvectis describes NXP200 (搜索) as having best-in-class potential, and the case rests on a specific gap. First-generation BRAF (搜索) drugs are already a large business, with Novartis's Tafinlar and Mekinist combination alone generating $2.2 billion in sales last year, but they eventually stop working in many patients, and those who relapse on them are left with few targeted options.
NXP200 (搜索) has already shown single-agent activity in patients previously treated with BRAF (搜索) inhibitors, the group where the older drugs run out of road. It is being developed across V600 mutations and the non-V600 BRAF mutations that first-generation drugs were not designed to address. Further data from the ongoing Phase 1b, including in BRAF-mutant tumor types beyond the brain, will test that differentiation.
Ciprocopan, the Approved Anchor Asset
NXP200 (搜索) is one part of the Nuvectis pipeline. The asset anchoring the company is ciprocopan (搜索) (NXP100), licensed from Haisco in the same June deal that brought in NXP200.
Ciprocopan (搜索) won its first marketing approval in China in July for patients with paroxysmal nocturnal hemoglobinuria (搜索) (PNH) who had not previously received a complement inhibitor. It is the first approval anywhere for a once-daily oral Factor B (搜索) inhibitor. The approval rested on a head-to-head Phase 3 trial against AstraZeneca's Soliris, the long-time standard of care, in which 59.5% of ciprocopan patients reached hemoglobin of 12 g/dL or higher, compared with 8.3% on Soliris.
A second application, for patients who have already failed C5 (搜索)-inhibitor therapy, is under review. Nuvectis plans to meet with the FDA ahead of a U.S. IND submission targeted for the fourth quarter.
An Oral Market in Motion
The market ciprocopan (搜索) is entering is moving toward oral therapy. Novartis's Fabhalta, the first oral Factor B (搜索) inhibitor on the U.S. market, grew sales from $169 million in the first quarter of 2026 to $225 million in the second, and Novartis places it in its $3 billion to $10 billion peak-sales tier. Fabhalta is taken twice a day, while ciprocopan is designed to be taken once, in a disease that requires treatment for life.
Near-Term Milestones
Nuvectis has several readouts and filings scheduled. NXP200 (搜索) will be presented orally at the European Society for Medical Oncology meeting in October. U.S. IND submissions for both ciprocopan (搜索) and NXP200 are targeted for the fourth quarter, and an update on NXP900's combination with osimertinib is expected by year-end.
The company notes that timelines can shift, and that a breakthrough designation speeds review rather than guaranteeing approval. According to company guidance, Nuvectis has cash into the first half of 2029 following a $115 million raise in July.